Clinical trial of epirubicin injection combined with cisplatin injection in the treatment of advanced resistant endometrial cancer
10.13699/j.cnki.1001-6821.2017.05.006
- VernacularTitle:表柔比星注射液联合顺铂注射液治疗晚期耐药性子宫内膜癌的临床研究
- Author:
Su-Hong FAN
1
;
Jun LIN
;
Jun-Yan MA
Author Information
1. 浙江大学医学院附属妇产科医院妇产科
- Keywords:
epirubicin injection;
cisplatin injection;
advanced resistant endometrial cancer;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(5):404-407
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of epirubicin injection combined with cisplatin injection in the treatment of advanced resistant endometrial cancer.Methods A total of 56 patients with advanced resistant endometrial cancer were divided into control group and treatment group with 28 cases per group.Control group received intravenous infusion of cisplatin injection 30 mg · m-2 at day 1,8 + fluorouracil 650 mg · m-2at day 1,8.Treatment group was given intravenous infusion of cisplatin injection 30 mg · m-2 at day 1,8 + epirubicin injection 40 mg · m-2at day 1.Two groups were treated for 2 cycles with 4 weeks per cycle.The clinical efficacy,ovarian cancer antigen (CA125),epididymis protein 4 (HE4),adiponectin (APN) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 85.71％ (24/28 cases) and 60.71％ (17/28 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:CA125 were (28.62±0.33),(40.52 ±0.45)U · L-1;HE4 were (1.57 ±0.24),(35.93 ±0.38)pmol · L-1;APN were (8.59 ± 0.98),(7.74 ± 0.78) μg · mL-1,the differences were statistically significant (P ＜ 0.05).The adverse drug reactions were based on hair loss,oral mucositis,nausea,vomiting,diarrhea and leucopenia in treatment group,which in control group were based on hair loss,loss of appetite,nausea,vomiting,leukopenia,thrombocytopenia and proteinuria.The incidences of adverse drug reactions in treatment and control groups were 21.43％ and 32.14％ without significant difference (P ＞ 0.05).Conclusion Epirubicin injection combined with cisplatin injection has a definitive clinical efficacy in the treatment of advanced resistant endometrial cancer,without increasing the incidence of adverse drug reactions.
